Quanterix Reports 20% Revenue Growth but Faces Margin Pressures
Event summary
- Quanterix reported $36.4M in Q1 2026 revenue, up 20% YoY from $30.3M.
- GAAP gross margin declined to 42.7% from 48.9% due to accounting policy changes.
- Adjusted EBITDA loss narrowed to $9.8M from $11.3M in the prior year.
- Company reaffirmed 2026 revenue guidance of $169M–$174M.
- Strategic collaborations announced with Tempus AI and Life Line Screening.
The big picture
Quanterix's Q1 2026 results reflect progress in scaling its biomarker diagnostics platform post-Akoya acquisition, but margin pressures highlight integration challenges. The company's strategic focus on Alzheimer’s diagnostics and partnerships with Tempus AI and Life Line Screening positions it in a growing precision medicine market. Success hinges on executing cost synergies and securing regulatory milestones.
What we're watching
- Margin Recovery
- Whether Quanterix can stabilize gross margins amid post-acquisition integration costs.
- Alzheimer's Diagnostics
- The pace at which FDA decisions and clinical utility studies advance the Alzheimer’s diagnostics business.
- Cash Flow Breakeven
- How soon Quanterix achieves cash flow breakeven in H2 2026 as planned.
Related topics